Telor Ophthalmic's Tekron
Executive Summary
Development halted for ethacrynic acid topical eye-drop formulation for reduction of intraocular pressure in patients with glaucoma. The Woburn, Mass.-based company says a Phase II trial of Tekron, administered twice daily for 14 days at the highest concentration used in Phase I trials, showed "no efficacy compared to the placebo in reducing intraocular pressure"